Growth Factors and Angiogenesis in Breast Cancer

  • A. L. Harris
  • E. Horak
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 127)


An overview of adjuvant therapy in breast cancer has shown the long-term survival benefits in node-positive and-negative cases [1] (reprinted in part in this volume). However, these treatments have still made only a relatively small impact on mortality, i.e. an increase in 10-year survival from 45% to 51.3% overall and from 39.8% to 46.6% in node-positive cases. Thus, the majority still die from their cancer. Greater understanding of the mechanisms of tumour growth and metastasis may enable the rational development of new agents to complement the achievements of hormone and chemotherapy.


Breast Cancer Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Status Imperial Cancer Research Fund Vascular Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71–85Google Scholar
  2. 2.
    Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMedCrossRefGoogle Scholar
  3. 3.
    Weidner MD, Semple JP, Welch WR, Folkman J (1991) Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRefGoogle Scholar
  4. 4.
    Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, Mason DY (1992) The heterogeneity of vascular endothelial cells with particular relevance to the diagnosis of vascular tumours. J Clin Pathol 45:143–148PubMedCrossRefGoogle Scholar
  5. 5.
    Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY (1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752–757PubMedCrossRefGoogle Scholar
  6. 6.
    Nicholson S, Sainsbury RC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL (1991) Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150PubMedCrossRefGoogle Scholar
  7. 7.
    Bicknell R, Harris AL (1991) Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 27:781–784PubMedCrossRefGoogle Scholar
  8. 8.
    Hughes CS, Irvin CG, Rockwell S (1991) Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. Cancer Commun 3:29–35PubMedGoogle Scholar
  9. 9.
    Coleman CN (1988) Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80:310–317PubMedCrossRefGoogle Scholar
  10. 10.
    Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID (1988) Mitomycin C resistance under aerobic but not hypoxic conditions in a mammalian cell line: association with impaired drug activation and decreased NADPH: cytochrome P-450 reductase activity. Cancer Res 50:775–778Google Scholar
  11. 11.
    Bligh HFJ, Bartoszek A, Robson CN, Hickson ID, Kasper CB, Beggs JD, Wolf CR (1990) Activation of mitomycin C by NADPH: cytochrome P-450 reductase. Cancer Res 50:7789–7792PubMedGoogle Scholar
  12. 12.
    Wireko FC, Abraham DJ (1991) X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin. Proc Natl Acad Sci USA 88:2209–2211PubMedCrossRefGoogle Scholar
  13. 13.
    Philip P, Harris AL, Rea D, Carmichael J, Rajagopalan B, Bedford P, Thompson C, Radda GK (1992) Phase I/II trial of left shifting agent BW12C and mitomycin C. Monitoring by magnetic resonance spectroscopy (MRS). Proc ASCO II:137Google Scholar
  14. 14.
    Review Issue (1991) Cell 64:235–364Google Scholar
  15. 15.
    Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI (1991) Transfection with protein kinase Ca confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181–189PubMedGoogle Scholar
  16. 16.
    Nuti M, Zupi G, D’Agnano I, Turchi V, Candiloro A, Frati L (1991) Antigenic expression changes occurring in Adriamycin resistant MCF-7 mammary carcinoma cells. Anticancer Res 11:1225–1230PubMedGoogle Scholar
  17. 17.
    Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35–43PubMedGoogle Scholar
  18. 18.
    Kawada M, Imoto M, Umezawa K (1991) Suppression of multidrug resistance by inostamycin in cultured human carcinoma KB cells. J Cell Pharmacol 2:138–142Google Scholar
  19. 19.
    Gschwendt M, Furstenberger G, Rose-John S, Rogers M, Kittstein W, Pettit GR, Herald CI, Marks F (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555–562PubMedCrossRefGoogle Scholar
  20. 20.
    Nutt JE, Harris AL, Lunec J (1991) Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-ß1 genes in breast tumour cells. Br J Cancer 64:671–676PubMedCrossRefGoogle Scholar
  21. 21.
    Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64:281–302PubMedCrossRefGoogle Scholar
  22. 22.
    Rea D, Prendiville J, Harris AL, Wolf P, Philip P, Carmichael J, Lewis C, Dallman M, Walker T, Sri-Pathmanathan R, Thatcher N, Crowther D (1992) A phase I study of bryostatin 1 - a protein kinase C partial agonist. EORTC-NIH, New Drugs Conference, AmsterdamGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • A. L. Harris
    • 1
  • E. Horak
    • 1
  1. 1.Molecular Oncology Laboratory, Imperial Cancer Research Fund LaboratoriesInstitute of Molecular Medicine, John Radcliffe HosptialOxfordUK

Personalised recommendations